CN111247132A - 四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用 - Google Patents

四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用 Download PDF

Info

Publication number
CN111247132A
CN111247132A CN201880046977.3A CN201880046977A CN111247132A CN 111247132 A CN111247132 A CN 111247132A CN 201880046977 A CN201880046977 A CN 201880046977A CN 111247132 A CN111247132 A CN 111247132A
Authority
CN
China
Prior art keywords
acid
compound
furan
nmr
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880046977.3A
Other languages
English (en)
Other versions
CN111247132B (zh
Inventor
孙青*
孙青�
张卫东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Qingdong Biotechnology Co ltd
Original Assignee
Shanghai Qingdong Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Qingdong Biotechnology Co ltd filed Critical Shanghai Qingdong Biotechnology Co ltd
Publication of CN111247132A publication Critical patent/CN111247132A/zh
Application granted granted Critical
Publication of CN111247132B publication Critical patent/CN111247132B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

一种四氢萘并[1,2‑b]呋喃‑2(3H)‑酮衍生物，其化学结构以式Ⅰ所示：(I)，及其制备方法。所述四氢萘并[1,2‑b]呋喃‑2(3H)‑酮衍生物可用于制备预防/治疗类风湿性关节炎疾病药物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880046977.3A 2017-07-14 2018-07-12 四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用 Active CN111247132B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710576021.1A CN109251191A (zh) 2017-07-14 2017-07-14 四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用
CN2017105760211 2017-07-14
PCT/CN2018/095359 WO2019011285A1 (zh) 2017-07-14 2018-07-12 四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用

Publications (2)

Publication Number Publication Date
CN111247132A true CN111247132A (zh) 2020-06-05
CN111247132B CN111247132B (zh) 2021-11-23

Family

ID=65001092

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710576021.1A Pending CN109251191A (zh) 2017-07-14 2017-07-14 四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用
CN201880046977.3A Active CN111247132B (zh) 2017-07-14 2018-07-12 四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710576021.1A Pending CN109251191A (zh) 2017-07-14 2017-07-14 四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用

Country Status (5)

Country Link
US (1) US11034663B2 (zh)
EP (1) EP3653614B1 (zh)
JP (1) JP7158060B2 (zh)
CN (2) CN109251191A (zh)
WO (1) WO2019011285A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021143853A1 (zh) * 2020-01-16 2021-07-22 上海青东生物科技有限公司 一种四氢萘并[1,2-b]呋喃-2(3H)-酮化合物及其晶型研究
CN112794832B (zh) * 2021-01-30 2022-06-24 河南中医药大学 一个从牛蒡叶中提取的具有抗炎活性的化合物nby-10及其制备方法与应用
CN112920148B (zh) * 2021-01-30 2023-11-14 河南中医药大学 一种从牛蒡叶中提取的具有抗炎活性的新化合物nby-16及其制备方法与应用
CN112851612B (zh) * 2021-01-30 2023-11-10 河南中医药大学 一种从牛蒡叶中提取的具有降低胆固醇活性化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101348729B1 (ko) * 2010-08-30 2014-01-08 한국생명공학연구원 유데스만계 화합물 및 이를 유효성분으로 함유하는 조성물
CN102499916A (zh) * 2011-11-29 2012-06-20 中国人民解放军第二军医大学 1β-羟基土木香内酯在制备防治类风湿关节炎的药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAO CHEN 等: "Discovery of Potent Small-Molecule Inhibitors of Ubiquitin-Conjugating Enzyme UbcH5c from α-Santonin Derivatives", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
高爽: "以泛素结合酶UbcH5c为靶标的倍半萜内酯类活性成分的发现及其抗炎作用研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Also Published As

Publication number Publication date
CN109251191A (zh) 2019-01-22
US11034663B2 (en) 2021-06-15
WO2019011285A1 (zh) 2019-01-17
EP3653614B1 (en) 2022-04-20
JP2020528079A (ja) 2020-09-17
US20200199089A1 (en) 2020-06-25
CN111247132B (zh) 2021-11-23
EP3653614A4 (en) 2020-12-30
JP7158060B2 (ja) 2022-10-21
EP3653614A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
CN111247132B (zh) 四氢萘并[1,2-b]呋喃-2(3H)-酮衍生物及其制备与在制药中的应用
WO2017104691A1 (ja) キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬
ES2802977T3 (es) Compuesto para la modulación inmunológica, uso del mismo y composición farmacéutica que lo comprende
JP2636847B2 (ja) ジアセチルライン塩及び関節炎の治療におけるそれらの使用
RU2587668C2 (ru) Производное замещенного циннамамида, способ его получения и применения
ES2832501T3 (es) Inhibidor del ácido carboxílico URAT1 que contiene estructura de diarilmetano, método de preparación y uso del mismo
RU2641285C2 (ru) Соединения хинина, способ их получения и их медицинское применение
AU2007275689A1 (en) AZA-peptide protease inhibitors
EP1451163A1 (en) 3-amido-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
CN101115737B (zh) 多巴胺激动剂的盐类形式
NO180117B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive betaaminoetyl-substituerte fenylforbindelser og nye utgangsforbindelser/mellomprodukter for anvendelse deri
JP2017078024A (ja) 新規テトラヒドロピリドピリミジノン誘導体
JP5903166B2 (ja) ブチルフタリドの誘導体、並びにその製造法及び使用
SU1053752A3 (ru) Способ получени производных эргол-8-ена или эрголина или их солей
KR20220152535A (ko) 신규 3,5-디아미노벤조산계 화합물, 및 이것을 사용한 Pin1 저해제 및 염증성 질환의 치료제
CN105272984B (zh) 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用
CN102234284B (zh) 含氟的噻氯匹啶类似物及其制备方法和用途
RU2704967C1 (ru) Карбоксамидные производные изоксазолина, способ их получения и применения для лечения воспалительных заболеваний
CN116003387B (zh) 一种氘代吲唑丙酰胺类化合物、药物组合物和用途
WO2013083014A1 (zh) 黄豆苷元衍生物、其药学上可接受的盐、制备方法以及包含其的药物组合物
US20230339911A1 (en) Pyridazinone compounds
CN102757440B (zh) 1-(6,7-二氢-5H-呋喃[3,2-g]色烯-3-乙酰基)-4-苯基哌嗪及其用途
CN117800938A (zh) 一种羟基取代贝前列素衍生物、合成方法及其应用
CN116082302A (zh) 氘代吲唑-吡啶-苯基-三氟乙基四取代烯烃类化合物及其用途
EA045400B1 (ru) Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220107

Address after: 201210 room 110, building 2, No. 230, Cailun Road, No. 86 Faraday Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: Shanghai Qingxuan Biotechnology Co.,Ltd.

Address before: 201306 2, building 979, Yun Han Road, mud town, Pudong New Area, Shanghai

Patentee before: SHANGHAI QINGDONG BIOTECHNOLOGY Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230506

Address after: 201306 2nd floor, no.979 Yunhan Road, Lingang New Area, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: SHANGHAI QINGDONG BIOTECHNOLOGY Co.,Ltd.

Address before: 201210 room 110, building 2, No. 230, Cailun Road, No. 86 Faraday Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee before: Shanghai Qingxuan Biotechnology Co.,Ltd.

TR01 Transfer of patent right